March 12, 2017

MockV Solutions Announces Publication of Mock Virus Particle Characterization Data in Applied Biochemistry and Biotechnology

Rockville, MD – March 12, 2017 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that a scientific manuscript detailing a characterization study of its non-infectious MVM-Mock Virus Particles (MVM-MVP) has been accepted for publication in the scientific journal Applied Biochemistry and Biotechnology (ABAB).

The study, conducted by the FDA, was part of collaboration between MockV Solutions and the FDA's Center for Drug Evaluation and Research. One of the key discoveries, reported in ABAB, pertained to the physicochemical similarity of MockV's non-infectious MVM-MVP's to live-infectious Minute Virus of Mice (MVM). Size, surface charge, and surface hydrophobicity data demonstrated that these critical characteristics for protein separation applications (ex. chromatography and nanofiltration) were similar among the two particle species. "This data implies that MVM-MVP's may be useful as an accurate surrogate to live MVM during chromatography or nanofiltration based biopharmaceutical process development and characterization experiments", said MockV Founder and CEO David Cetlin. "MockV's goal is to provide these BSL-1 compatible particles as part of a commercial kit that would help scientists design robust viral clearance into their biopharmaceutical processes. This vision dovetails with 'Quality by Design' principles and aligns nicely with similar products on the market such as Host Cell Protein and residual Protein A Kits."

A link to the article is provided here:

http://link.springer.com/article/10.1007/s12010-017-2447-y

Full text of the article will be available in an upcoming print version of the journal or through contacting MockV Solutions at: dcetlin@mockvsolutions.com

About MockV Solutions Inc.

MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactive virus, a contaminant of great concern during the manufacturing of biopharmaceuticals. These products are only approved for clinical

or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging "spiking studies". The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements - jeopardizing the timely approval of potentially life-altering therapies. MockV's lead product candidate, the MVM_{MVP} Kit contains a non-infectious "Mock Virus Particle" (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution. Currently, this business segment is supported by a $100,000 convertible note from the Technology Commercialization Fund of The Maryland Technology Development Corporation (TEDCO)

For further information regarding MockV Solutions, Inc., please visit the Company's website at www.mockvsolutions.com.